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Background: We aimed at exploring potential pathophysiological processes across psychotic 
disorders, applying metabolomics in a large and well-characterized sample of patients and 
healthy controls. 
Methods: Patients with schizophrenia and bipolar disorders (N = 212) and healthy controls 
(N = 68) had blood sampling with subsequent metabolomics analyses using electrochemical 
coulometric array detection. Concentrations of 52 metabolites including tyrosine, tryptophan 
and purine pathways were compared between patients and controls while controlling for 
demographic and clinical characteristics. Significant findings were further tested in 
medication-free subsamples.   
Results: Significantly decreased plasma concentrations in patients compared to healthy 
controls were found for 3-hydroxykynurenine (3OHKY, p = 0.0008), xanthurenic acid 
(XANU, p = 1.5*10-5), vanillylmandelic acid (VMA, p = 4.5*10-5) and metanephrine (MN, p 
= 0.0001). Plasma concentration of xanthine (XAN) was increased in the patient group (p = 
3.5*10-5). Differences of 3OHKY, XANU, VMA and XAN were replicated across 
schizophrenia spectrum disorders and bipolar disorders subsamples of medication-free 
individuals. 
Conclusions: Although prone to residual confounding, the present results suggest the 
kynurenine pathway of tryptophan metabolism, noradrenergic and purinergic system 
dysfunction as trait factors in schizophrenia spectrum and bipolar disorders. Of special 








Schizophrenia and bipolar disorder are highly heritable disorders with phenotypic and 
genotypic overlap (Lichtenstein et al., 2009; Tesli et al., 2014). Despite intensive research, 
the underlying mechanisms are still unresolved (Grande et al., 2016; Owen et al., 2016). To 
enable better treatments and potentially preventive measures, there is a continuing need for 
research pursuing pathophysiological components by taking advantage of new and advanced 
methods for mapping of biological processes.  
The complexity of neuroactive substances and signaling involved in mental processes 
imply the need for comprehensive assessments of signaling pathways and physiological 
processes to unveil the mechanisms of severe mental disorders. Metabolomics, the analysis of 
a broad spectrum of metabolites from the metabolic processes and interactions in the body, is 
an emerging method enabling characterization of the actual metabolic status of an individual 
(Kaddurah-Daouk & Krishnan, 2009; Guest et al., 2015; Sethi & Brietzke, 2015). 
Metabolomics have already been applied in both central and peripheral tissues in severe 
mental disorders and other brain disorders (Yao et al., 2010a; Yao et al., 2010c; Condray et 
al., 2011; Yao et al., 2012; Kaddurah-Daouk et al., 2012; Motsinger-Reif et al., 2013; 
Kaddurah-Daouk et al., 2013a; Fazio et al., 2015; Zhang et al., 2016; Rotroff et al., 2016; 
Gupta et al., 2016). These studies have identified several potential biomarkers (Oresic et al., 
2011; Kaddurah-Daouk et al., 2012; Yoshimi et al., 2016), being able to distinguish 
diagnostic groups from healthy controls (Bicikova et al., 2013; Motsinger-Reif et al., 2013; 
Fukushima et al., 2014; Liu et al., 2014; Xu et al., 2014; Tasic et al., 2017). Disease-related 
processes indicated by biomarkers from metabolomics studies include such as 
neurotransmission, energy metabolism, mitochondrial functioning and oxidative stress (Sethi 
& Brietzke, 2015).  
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Despite promising results, metabolomics is a novel approach and studies of severe 
mental disorders suffer from essential shortcomings. These include potential for confounding 
effects of medication and other extraneous factors (Turck & Filiou, 2015) and risk of type 1 
errors due to multiple testing based on a broad range of metabolites. To overcome these 
limitations, large and well-characterized samples of patients and healthy controls are needed 
to be able to control for several confounders, including analyzes of metabolite levels in 
individuals free from psychotropic drugs and other medications. Moreover, the use of large 
samples across psychotic disorders makes it possible to alleviate the issue of multiple testing. 
As bipolar disorders and schizophrenia spectrum disorders are pathophysiological related 
disorders (Cardno & Owen, 2014; Volk et al., 2016) metabolite findings of one group could 
be tested in the other diagnostic group. Being able to replicate findings across the two 
disorders would strengthen the findings and simultaneously indicate mechanisms in common 
for the disorders. 
 In the present metabolomics study, we investigated a predefined range of metabolites 
including monoamine-, purine- and sulfur amino acid pathways, in a large sample of both 
bipolar and schizophrenia spectrum disorders. We aimed at identifying pathophysiologically 
related metabolites targeting well-known candidate pathways of psychosis spectrum disorders 
mechanisms. We hypothesized dysregulations mainly related to tryptophan, tyrosine and 
purine pathways as established pathophysiological candidates involving dopamine, 
norepinephrine, epinephrine, serotonin and purine metabolism (Gysin et al., 2007; Michel et 
al., 2011; Ortiz et al., 2015; Grande et al., 2016; Owen et al., 2016; Lieberman and First, 
2018), and with conclusions based on replicated findings in the two diagnostic groups in 






Patients were included through the ongoing Thematically Organized Psychosis (TOP) Study 
carried out at the University Hospitals of Oslo, Norway. General inclusion criteria for the 
TOP study are 1) being registered in the psychiatric services of any one of the participating 
hospitals, 2) age 18 to 65 years, 3) meeting the Diagnostic and Statistical Manual of Mental 
Disorders (DSM)-IV criteria for bipolar or schizophrenia spectrum disorders, and 4) to be 
willing and able to give written, informed consent to participation. General exclusion criteria 
are a history of moderate or severe head injury, serious somatic illness, neurological disorder 
and mental retardation.  
Included in the current substudy were consecutively referred patients (N = 212) and a 
healthy control group (N = 68) included from 2004 to 2013, with metabolomics 
measurements. Duration of illness (median [interquartile range]) was 4 (9) years for the total 
patient sample and 7 (16) years for the unmedicated (N = 52) patients. The patients had a 
DSM-IV Schizophrenia and Other Psychotic Disorders diagnosis, excluding Psychotic 
Disorder Due to a General Medical Condition and Substance-Induced Psychotic Disorder, in 
the following termed “schizophrenia spectrum” (SCZ, N = 139 [25 unmedicated]), or any 
type of DSM-IV Bipolar Disorder diagnosis, in the following termed “bipolar disorder” (BD, 
N = 73 [27 unmedicated]). The reason for not receiving medication was usually early phase of 
disease or discontinuation. The healthy control group (N=68, [50 unmedicated], 18 typically 
used over-the-counter painkillers, contraceptives or antiallergics) was randomly selected from 
statistical records from the same catchment area as the patients. Table 1 shows the sample 
characteristics.  
 
Clinical assessments  
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Inclusion and diagnostic interviews were done by trained medical doctors and psychologists 
using The Structured Clinical Interview for DSM-IV Axis I Disorders, SCID 1 (First et al., 
1995). The Inventory of Depressive Symptomatology-Clinician Rated (IDS-C, BD group) 
(Rush et al., 1996), Calgary depression scale for schizophrenia (CDSS, SCZ group) 
(Addington et al., 1990), Young Mania Rating Scale (YMRS) (Young et al., 1978), the 
Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) 
(Kay et al., 1987), and Global Assessment of Functioning, symptom scale (GAF-S) (Pedersen 
et al., 2007) were used for symptom assessments (table 1).  
In addition, a series of clinical characteristics were assessed including illicit drug use 
(number of times used last two weeks), use of tobacco (yes/no), body mass index (BMI) and 
diet (complete list given in table 1). Diet was assessed by interview as very or moderate 
unhealthy or healthy during the last six months, and dichotomized as unhealthy (very or 
moderate) or healthy in the analyses. The items early morning awakening from IDS and 
CDSS were used as a measure of sleep pattern (Mukherjee D et al., 2018). 
 
Sample collection and metabolomics concentration analyses 
Blood was drawn from the antecubital vein in the morning while participants were fasting. 
The sample was centrifuged for 15 min at 1200 x g while temperature was kept at 4 oC in a 
cooled centrifuge. Then the plasma was rapidly collected in a conic tube and immediately 
frozen at -80 oC. All samples were collected and prepared by the same personnel at the same 
laboratory. 
 Plasma samples were analyzed using a liquid chromatography electrochemical array 
(LCECA) platform that has been extensively validated and used in our prior studies in 
neurodegenerative and psychiatric disorders (Rozen et al., 2005; Bogdanov et al., 2008; 
Johansen et al., 2009; Zhu et al., 2013; Kaddurah-Daouk et al., 2013b). Targeted assays with 
7 
 
the LCECA platform include compounds from the tyrosine, tryptophan, purine and sulfur 
amino acid pathways, vitamins, oxidative, nitrative and methylation markers and a number of 
drugs and metabolites. The complete list of metabolites analyzed is shown in table 2. 
 
Ethics 
The investigation was carried out in accordance with the Declaration of Helsinki. After 
complete description of the study to the subjects, written informed consent was obtained. The 
Regional Ethics Committee and The Norwegian Data Inspectorate approved the study. The 
Norwegian Directorate of Health approved the biobank. 
 
Statistical analysis 
For testing between-group differences of demographic and clinical data we used Mann-
Whitney U test and chi-square test for continuous and categorical variables, respectively 
(table 1). Metabolite plasma concentrations were compared between all patients and healthy 
controls and between SCZ and BD with ANCOVA, applying adjustments with backward 
elimination of number of affective episodes, number of psychotic episodes (proxies for 
duration of illness and illness course), BMI, GAF-S (for comparison of SCZ and BD), age and 
sex. Due to skewed distributions, metabolite concentrations were transformed using 
logarithmic, square root and inverse transformations as appropriate. Number of psychotic and 
affective episodes were set at zero for healthy controls. The Mann-Whitney U test was used 
for variables not fulfilling criteria for parametric analyses (see table 2).  
To further test the significant associations of the main analyses for potential 
confounding of the demographic and clinical variables not recorded in healthy controls (use 
of illicit drugs, alcohol and tobacco; diet; level of symptoms [general; affective, including 
sleep pattern; and psychosis]), we first identified the variables significantly associated with 
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metabolite concentrations in the patient group (table 3). Secondly, we grouped patients 
according to being below or above (defined as equal or above) the median (continuous 
variables) and according to the categories (dichotomous variables) of these variables. We then 
compared metabolite concentrations of each of these subgroups of patients with those of the 
healthy control group. Spearman’s rho was applied for the association analyses between 
metabolite concentrations and continuous clinical variables and independent samples t-tests 
were applied for analyses across groups (Mann-Whitney U test for 2,5 dihdroxyphenylacetic 
acid [HGA]) (table 3).   
Level of significance was set at p < 0.00096 for the testing of metabolite concentration 
differences in the total patient sample of both medicated and medication-free individuals 
versus healthy controls, to correct for multiple statistical testing (a total of 52 metabolites). 
Significant findings in the total patient sample were further tested using ANCOVA with 
adjustments for sex and age in only medication-free individuals for replicated differences in 
both SCZ and BD separately at the level of p < 0.05; significant findings in the psychosis 
spectrum group, SCZ, are only reported if findings in the more uniform group of patients with 
a schizophrenia specific diagnosis (SZdiagn) were insignificant.  
 
Results 
Metabolite concentrations in patients and healthy controls  
Total patient sample versus healthy controls 
Plasma concentrations of 3-hydroxykynurenine (3OHKY), xanthurenic acid (XANU), 
xanthine (XAN), vanillylmandelic acid (VMA) and metanephrine (MN) differed significantly 
in the total patient sample compared to the healthy controls in analyses independent of 
medication status. Lower concentrations in patients versus healthy controls were found for 
3OHKY (F = 11.5, df = 1, p = 0.0008, figure 1a), XANU (F = 19.5, df = 1, p = 1.5*10-5, 
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figure 1b), VMA (F = 17.2, df = 1, p = 4.5*10-5, figure 1c) and MN (F = 15.0, df = 1, p = 
0.0001). Higher plasma concentrations in patients vs healthy controls were found for XAN (F 
= 17.7, df = 1, p = 3.5*10-5, figure 1d). For p-values of metabolite comparisons between all 
patients and healthy controls not given in the main text, please see supplementary table S1.  
 
BD versus SCZ 
Glutathione (reduced) was lower in BD compared to SCZ (p = 0.017), and 5-
hydroxytryptophan higher in BD compared to SCZ (p = 0.037). Otherwise there were no 
significant metabolite concentration differences between BD and SCZ. 
 
BD and SCZ medication-free subsamples versus healthy controls 
Of those metabolites with significantly different plasma levels in the total patient sample 
compared to healthy controls, significantly lower plasma concentration of 3OHKY (SCZ [p = 
0.021]; BD [p = 0.013], figure 1a), XANU (SZdiagn [p = 0.007]; BD [p = 0.0002], figure 1b) 
and VMA (SCZ [p = 0.027]; BD [p = 0.003], figure 1c), and significantly higher plasma 
concentration of XAN (SCZ [p = 0.002]; BD [p = 0.013], figure 1d) were found across SCZ 
and BD medication-free subsamples. MN did not differ significantly from healthy controls in 
SCZ or BD medication-free subsamples. 
 Lower plasma concentration of HGA were suggested across SCZ (p = 0.011) and BD 
(p = 0.033) medication-free subsamples based on a trend level lower concentration in the total 
patient sample (p = 0.003, supplementary figure S1). Lower plasma concentrations of 
dopamine were suggested in all patients (trend level, p = 0.00097) compared to healthy 
controls, but were not replicated across SCZ (ns) and BD (p = 0.014) in medication-free 
subsamples. Otherwise there were no metabolites with significant differences in both the 




Metabolite concentrations and sample characteristics 
Significant associations between metabolite plasma concentrations and sample characteristics 
not recorded in healthy controls, including affective and psychosis symptoms, are given in 
table 3. To control for potential confounding of these variables, metabolite concentrations in 
subgroups of patients were compared to metabolite concentrations among (all) healthy 
controls.  
 
3OHKY, XANU, VMA, XAN, MN and HGA 
Diet: Plasma concentration of XANU was significantly lower in patients with healthy (p < 
0.001) and unhealthy (p = 0.002) diet compared to healthy controls.  
Illicit drugs: Plasma concentrations of 3OHKY were significantly lower in patients with and 
without use of illicit drugs compared to healthy controls (both p < 0.001). 
Symptoms: Higher plasma concentrations of MN were associated with less symptoms on 
several rating scales (GAF-S, SCI-PANSS and CDSS [SCZ]) and higher levels of HGA were 
associated with lower GAF-S scores; significantly lower concentrations of MN and HGA in 
patients were shown in the subgroups with symptom scores below (trend level significance 
for HGA) and above the median symptom scores, compared to healthy controls (table 3). 
Plasma concentrations of 3OHKY and XANU were not associated with symptom levels. 
Sleep pattern measured as early morning awakening was not significantly associated with the 
metabolite concentrations. 
Metabolite concentrations of VMA and XAN were not significantly associated with 
the demographic or clinical variables. Further details of statistical associations of metabolite 
concentrations and demographic and clinical variables and subgroup analyses for 3OHKY, 





The main findings of the present study are decreased plasma concentration of 3OHKY, 
XANU and VMA and increased concentration of XAN across diagnostic categories in 
psychotic disorders. Differences in metabolite concentrations were significant in the overall 
patient group and confirmed across subsamples of schizophrenia spectrum and bipolar 
disorders in medication-free individuals. Although not reaching statistical significance after 
correcting for multiple testing, data were also suggestive of decreases in HGA across SCZ 
and BD. Decreased concentration was found for MN in the overall patient group; however, 
without being replicated across the medication-free subsamples.   
 The present findings in the kynurenine pathway is in line with the pathway being 
increasingly implicated in the pathogenesis of SCZ and BD in recent years (Erhardt et al., 
2017). Kynurenic acid has antagonistic effects on NMDA receptors and seems to be increased 
at central levels in psychotic disorders (Erhardt et al., 2017; Plitman et al., 2017). In line with 
the present findings, 3OHKY and its metabolite XANU of the kynurenine pathway were 
recently reported decreased in serum of patients with SCZ (Fazio et al., 2015). The same 
study reported decreased XANU in relatives of the patients and suggested XANU as a trait 
marker and potentially a drug target in SCZ. XANU is reported in neurons in the rodent brain 
(Gobaille et al., 2008; Roussel et al., 2016), it seem to influence glutamate synaptic 
transmission (Neale et al., 2013; Fazio et al., 2015) and with a suggested role in cognition 
(Sathyasaikumar et al., 2017). The present findings replicate deficient levels of 3OHKY and 
XANU in SCZ, and expand the finding to include BD in line with the psychosis continuum 
hypothesis (Lichtenstein et al., 2009; Van Snellenberg & de, 2009; Tesli et al., 2014). 
Although kynurenine pathway dysfunction has previously been linked to BD pathophysiology 
(Sellgren et al., 2016), this is to the best of our knowledge the first data indicating reduced 
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levels of XANU in BD. Potential mechanisms of kynurenine pathway dysfunction in 
psychotic disorders include genetic and immune regulatory mechanisms (Wonodi et al., 2011; 
Kegel et al., 2014; Chaves Filho et al., 2018). Cytokines are regulatory factors in the 
conversion of tryptophan to N-formylkynurenine, catalyzed by the enzymes indoleamine 2,3-
dioxygenase and tryptophan 2,3-dioxygenase (Chaves Filho et al., 2018). In a study of bipolar 
disorder, Sellgren et al. (2016) recently reported an association between the minor allele of a 
SNP at 1p21.3 and increased kynurenic acid mediated by cytokine activation. Interestingly, 
immunological pathogenetic mechanisms are amongst the most robust novel findings in 
psychotic disorders (Dieset et al., 2012; Aberg et al., 2013; Volk et al., 2015; Hartwig et al., 
2017). Furthermore, dysregulation of the kynurenine pathway seem to be common to several 
mental disorders (Aarsland et al., 2015; Lim et al., 2016), indicating shared etiological factors 
in line with recent evidence of broad genetic correlations across mental disorders (Anttila et 
al., 2018).   
Plasma concentrations of kynurenine and related metabolites other than 3OHKY and 
XANU, did not differ between patients and healthy controls in the overall sample or in the 
medication-free subsamples of SCZ and BD. In line with the present results, a recent 
systematic review and meta-analysis found no significant difference in peripheral kynurenic 
acid levels, but increased central levels in SCZ compared to controls (Plitman et al., 2017). In 
BD, normal blood levels of kynurenine, 3OHKY and anthranilic acid and reduced kynurenic 
acid relative to healthy controls were recently reported (Birner et al., 2017). In a study using 
skin fibroblasts, increased production of 3OHK and kynurenic acid was indicated in BD, as 
well as in SCZ (Johansson et al., 2013). In the present sample, unaltered levels of kynurenine, 
kynurenic acid and anthranilic acid and decreased levels of 3OHKY were consistent across 
the overall sample and medication-free subsamples. Further data are needed to determine the 
characteristics of kynurenine pathway metabolites at peripheral levels (Erhardt et al., 2017); 
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divergent findings between studies could be due to the impact of several factors, including 
clinical characteristics (Carlborg et al., 2014; Chiappelli et al., 2014) and 
psychopharmacological agents. Importantly, contrary to the present study, all patients in the 
samples of Johansson et al. (2013) and Birner et al. (2017) used psychopharmacological 
agents, making analyses independent of medication status impossible. 
Significantly increased levels of XAN are in line with the established hypothesis of 
purinergic system dysfunction in psychotic disorders (Michel et al., 2011; Yao et al., 2013; 
Ortiz et al., 2015; Bartoli et al., 2016). XAN is oxidized to uric acid by the enzyme xanthine 
oxidase as the last step of purine catabolism (Day et al., 2016). The purinergic system is 
essential in brain function by various processes including energy metabolism and 
neurotransmission (Lindberg et al., 2015). Studies of peripheral levels have indicated 
increased uric acid in BD (Albert et al., 2015; Bartoli et al., 2016; Bartoli et al., 2017b). 
Decreased levels have been suggested in SCZ (Reddy et al., 2003; Yao et al., 2010b). Few 
studies have reported on XAN in psychotic disorders; however, two studies with mixed 
samples consisting of about 35% BD, indicated associations between cerebrospinal fluid 
XAN and hypoxanthine levels and depressive symptomatology and monoamine metabolites 
(Agren et al., 1983; Niklasson et al., 1983). Furthermore, Yao et al. (2010b) reported 
unaltered XAN, but increased xanthosine plasma levels, a metabolite interconverting to XAN, 
in neuroleptic- naive first episode psychosis patients. The authors suggest a metabolic shift 
towards xanthosine. In the present sample, xanthosine levels were similar across patients and 
healthy controls. Importantly, the current patient sample is larger, and with replicated findings 
across SCZ and BD in medication-free individuals. Uric acid levels were unaltered in patients 
compared to healthy controls; however, the finding of increased XAN in both SCZ and BD 
support purinergic system dysfunction as a trait component in common across psychotic 
disorders. The underlying mechanism is unclear, but could be linked to alterations in xanthine 
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oxidase activity (Akyol et al., 2002; Brunstein et al., 2005; Michel et al., 2011; Bartoli et al., 
2017a).  
There were reduced plasma levels of the epinephrine metabolite MN and the in 
common metabolite VMA of epinephrine and norepinephrine relative to healthy controls in 
the overall patient sample. However, only VMA was replicated across the diagnostic 
categories. Norepinephrine have been linked to the pathophysiology of both BD (Manji et al., 
2003) and SCZ (Fitzgerald, 2014; Maletic et al., 2017), and the precursor of VMA, 3-
Methoxy-4-hydroxyphenylglycol (MHPG) (Goldstein et al., 2003), have been associated with 
symptom scores of both disorders (Maas et al., 1993; Kurita et al., 2014). Thus, decreased 
plasma levels of VMA in the present patient sample support the hypothesis of noradrenergic 
dysfunction in psychosis spectrum disorders. Indicated reductions of HGA in SCZ and BD 
and of dopamine similarly suggest alterations related to tyrosine metabolism. To the best of 
our knowledge, the suggested association of HGA with psychotic disorders has not previously 
been reported.  
The current study has noteworthy strengths. Due to the well characterized sample of 
related psychotic disorders, we were able to utilize the large size of the overall sample by 
combining the various diagnostic categories as well as testing associations with an extensive 
range of potential confounders. Despite phenotypic differences, there are solid evidence of 
overlapping pathogenetic factors between SCZ and BD (Lichtenstein et al., 2009; Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013), and we were able to confirm 
findings indicated from the total sample in small well-defined medication-free independent 
diagnostic subsamples (SZdiagn or SCZ and BD). This procedure reduces the possibility of 
type 1 errors. Importantly, there were only differences between SCZ and BD in two of 52 
metabolites (p-value levels of 0.02 and 0.04) and no significant differences of 3OHKY, 
XANU, VMA, MN or XAN. 
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Conclusions about the direction of effects are tentative due to the cross-sectional 
design. However, the present significant findings generally involve pathways previously 
suggested in the pathophysiology of psychotic disorders. Moreover, a broad range of 
demographic and clinical variables did not seem to explain the main findings. Due to non-
normality of some metabolite concentrations and recording of several characteristics only in 
patients (use of illicit drugs, alcohol and tobacco; diet; level of symptoms [general; affective, 
including sleep pattern; and psychosis]), we were unable to perform statistical adjustments of 
these variables in the main analyses. However, separate analyses of associations between 
demographic and clinical variables and the metabolite plasma concentrations were performed. 
Importantly, higher plasma levels of XANU in patients with unhealthy diet and lower levels 
of 3OHKY in patients using illicit drugs, seem unable to explain lower metabolite levels in 
patients compared to controls, due to corresponding significant differences in analyses of 
subgroups of patients (table 3). Nevertheless, it should be noted that the findings might be 
prone to residual confounding including stress-related changes (Chiappelli et al., 2014); 
however, the stress system has been implicated in the pathophysiology of psychotic disorders 
(van Winkel et al., 2008). The subgroup analyses of medication-free individuals could be 
susceptible to bias, and the re-identification of significant metabolites in the subsamples could 
be seen as likely, although the patient subsample were only 25 % of the total patient sample. 
Moreover, the assay variation of the metabolites of the current study was not available; 
however, the analysis platform has been extensively validated and used in a range of prior 
studies (see Methods section).      
We measured peripheral metabolite levels as compared to central levels. This 
complicates the interpretation of the results. Metabolites of pathways indicated as 
dysfunctional in the present analyses, cross the blood-brain barrier (Esler et al., 1995; 
Gobaille et al., 2008; Bowman et al., 2010), giving grounds for peripheral sampling; 
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however, dynamics are uncertain. Correlations of MN and HGA with symptom measures 
suggest central communication. In the case of the kynurenine pathway, peripheral kynurenine 
and probably 3OHKY readily crosses the blood-brain barrier and influence the central 
kynurenine pathway metabolism (Fukui et al., 1991; Schwarcz et al., 2012; Hestad et al., 
2017), indicating the utility of blood sampling, especially as the method enables a large 
sample without being distressing or conferring risk of serious complications as with lumbar 
puncture (Wright et al., 2012). Moreover, peripheral measurements is a widely used method 
in psychiatric research of metabolic processes (Grossman & Potter, 1999; Bicikova et al., 
2013; Albert et al., 2015; Fazio et al., 2015; Bartoli et al., 2016; Birner et al., 2017). Also, 
studies of brain samples have the inherent risk of biases due to the postmortem interval 
(Lewis, 2002). The selection of metabolites could influence the interpretation of the findings. 
Several metabolites were not measured, including quinolinic acid and picolinic acid of the 
kynurenine pathway. Interestingly, a recent study of IgA responses to tryptophan catabolites 
in deficit and nondeficit schizophrenia reported increased responses to quinolinic acid, 
picolinic acid, 3OHKY and XANU; however, the relation to serum levels is unclear 
(Kanchanatawan et al., 2018). The reason for dysregulation of only certain metabolites of the 
pathways is unclear, but indicate complex regulatory mechanism.         
In conclusion, the results indicate dysfunctions of the kynurenine pathway and the 
noradrenergic and purinergic system in common across SCZ and BD. Of special interest is the 
association with XANU, a metabolite with recently revealed features relevant for psychotic 
disorders and previously not focused in BD. The study was able to take advantage of the 
psychosis continuum model by confirming associations from the total patient sample in 
medication-free independent subsamples of SCZ and BD, thus strengthening the findings as 
well as indicating pathophysiological mechanisms in common for the psychosis continuum. 
The present findings may contribute to the understanding of the pathophysiology of psychotic 
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disorders and the possibility of better pharmacological treatment. Future studies may aim to 
include large well-characterized samples with targeted metabolomic, immune and genetic data 
to further disentangle specific gene x environmental mechanisms. Moreover, longitudinal 
designs combining peripheral and central assessments would be of major benefit to elucidate 
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Figure 2. Box plots of plasma concentration measured in ng/ml of (a) 3-hydroxykynurenine 
(3OHKY), (b) xanthurenic acid (XANU), (c) vanillylmandelic acid (VMA) and (d) xanthine 
(XAN) with significant differences in both Schizophrenia or Schizophrenia spectrum 
disorders and Bipolar disorder samples relative to healthy controls in medication-free (left 
side of plots) individuals; the right side of the plots shows the respective blood concentrations 
of the total sample of patients vs. healthy controls independent of medication status. The 
boxes represent 25th and 75th percentiles and whiskers represent 1.5 times the interquartile 
range. Markers for particularly high plasma concentration values (ng/ml) of unmedicated 
bipolar disorder ([a]: 87.0), unmedicated healthy controls ([b]: 307.2; [c]: 274.3, 348.7, 
365.7), all patients ([a]: 87.0, 97.6, 149.6, 154.8, 223.4, 236.2; [b]: 294.2; [c]: 430.7; [d]: 
359.9) and all healthy controls ([a]: 91.2, 112.9; [b]: 307.2; [c]: 274.3, 348.7, 365.7; [d]: 
251.3, 378.3) are omitted from the plots to get a suitable scaling of the y-axis. 
*p < 0.05, **p ≤ 0.01 and ***p < 0.001 vs. healthy controls. 
 
 
